ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tetanus-Diphtheria booster

Its studies are mostly in Papillomavirus Infections, led by PT Bio Farma.

Furthest: phase 3, since Sep 11, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PT Bio Farma11 open or runningphase 3since Sep 11, 2026Sep 11, 2026Dec 31, 2026phase 3 · NCT07824310

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2026First study: phase 3 study in Papillomavirus InfectionsFirst studyNCT07824310 · 266 planned · Indonesia

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Papillomavirus InfectionsNCT07824310

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07824310Papillomavirus Infections · Indonesia3Not yet recruitingDec 31, 2026266

How it is read

Names in the registry

  • “Tetanus-Diphtheria booster”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.